Nancy MacDonald Rodig, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lymphoproliferative Disorders | 4 | 2024 | 527 | 1.570 |
Why?
|
| Kidney Transplantation | 19 | 2024 | 4268 | 1.530 |
Why?
|
| Renal Insufficiency, Chronic | 4 | 2022 | 2299 | 0.790 |
Why?
|
| Epstein-Barr Virus Infections | 2 | 2023 | 616 | 0.680 |
Why?
|
| Urogenital Abnormalities | 4 | 2023 | 255 | 0.600 |
Why?
|
| Organ Transplantation | 3 | 2023 | 1173 | 0.570 |
Why?
|
| Kidney Failure, Chronic | 4 | 2024 | 2495 | 0.560 |
Why?
|
| Clostridium Infections | 1 | 2023 | 562 | 0.520 |
Why?
|
| Polyomavirus Infections | 3 | 2021 | 192 | 0.450 |
Why?
|
| Tumor Virus Infections | 3 | 2021 | 437 | 0.430 |
Why?
|
| Urinary Tract | 4 | 2021 | 305 | 0.430 |
Why?
|
| Vesico-Ureteral Reflux | 4 | 2023 | 433 | 0.390 |
Why?
|
| Genetic Diseases, X-Linked | 1 | 2015 | 386 | 0.370 |
Why?
|
| BK Virus | 3 | 2021 | 120 | 0.370 |
Why?
|
| Growth Disorders | 1 | 2014 | 635 | 0.320 |
Why?
|
| Nephrolithiasis | 2 | 2022 | 117 | 0.310 |
Why?
|
| Kidney | 9 | 2023 | 7063 | 0.310 |
Why?
|
| Body Height | 1 | 2014 | 1565 | 0.290 |
Why?
|
| Child | 22 | 2024 | 80771 | 0.250 |
Why?
|
| Immunosuppressive Agents | 6 | 2024 | 4210 | 0.250 |
Why?
|
| Body Mass Index | 3 | 2022 | 13048 | 0.240 |
Why?
|
| Nephrotic Syndrome | 2 | 2017 | 381 | 0.220 |
Why?
|
| Antilymphocyte Serum | 2 | 2023 | 490 | 0.200 |
Why?
|
| Kidney Diseases, Cystic | 1 | 2023 | 182 | 0.190 |
Why?
|
| Graft Rejection | 5 | 2023 | 4498 | 0.190 |
Why?
|
| Receptors, Purinergic P2 | 1 | 2022 | 152 | 0.190 |
Why?
|
| Kidney Diseases | 3 | 2024 | 2099 | 0.180 |
Why?
|
| Quality of Life | 1 | 2022 | 13485 | 0.180 |
Why?
|
| Forkhead Transcription Factors | 2 | 2020 | 1626 | 0.180 |
Why?
|
| Pedigree | 5 | 2020 | 4539 | 0.180 |
Why?
|
| Genetic Testing | 3 | 2024 | 3591 | 0.160 |
Why?
|
| Living Donors | 2 | 2023 | 647 | 0.150 |
Why?
|
| Blood Proteins | 1 | 2003 | 1190 | 0.150 |
Why?
|
| Hyperoxaluria, Primary | 1 | 2017 | 25 | 0.150 |
Why?
|
| Urinary Tract Infections | 2 | 2017 | 804 | 0.140 |
Why?
|
| Oxalates | 1 | 2017 | 99 | 0.140 |
Why?
|
| Nephrocalcinosis | 1 | 2017 | 51 | 0.140 |
Why?
|
| Ligands | 1 | 2023 | 3273 | 0.130 |
Why?
|
| Neurofibromin 1 | 1 | 2018 | 190 | 0.130 |
Why?
|
| Nephrectomy | 2 | 2019 | 928 | 0.130 |
Why?
|
| Renal Insufficiency | 2 | 2012 | 812 | 0.130 |
Why?
|
| Neoplasms | 1 | 2024 | 22350 | 0.120 |
Why?
|
| Urothelium | 1 | 2017 | 275 | 0.120 |
Why?
|
| Humans | 40 | 2024 | 767040 | 0.120 |
Why?
|
| Genetic Markers | 2 | 2017 | 2602 | 0.120 |
Why?
|
| Child, Preschool | 14 | 2020 | 42606 | 0.110 |
Why?
|
| Mutation | 5 | 2020 | 30211 | 0.110 |
Why?
|
| Neurofibromatoses | 1 | 2018 | 303 | 0.110 |
Why?
|
| Incidence | 5 | 2024 | 21526 | 0.110 |
Why?
|
| Retrospective Studies | 12 | 2023 | 81659 | 0.110 |
Why?
|
| Fatal Outcome | 3 | 2015 | 1836 | 0.110 |
Why?
|
| Glomerular Filtration Rate | 1 | 2022 | 2227 | 0.110 |
Why?
|
| Adolescent | 14 | 2021 | 89046 | 0.110 |
Why?
|
| Anemia, Hemolytic, Autoimmune | 1 | 2014 | 147 | 0.100 |
Why?
|
| Syndrome | 2 | 2018 | 3271 | 0.100 |
Why?
|
| Infant | 11 | 2020 | 36485 | 0.100 |
Why?
|
| DNA Mutational Analysis | 2 | 2017 | 4114 | 0.100 |
Why?
|
| Metabolism, Inborn Errors | 1 | 2014 | 291 | 0.100 |
Why?
|
| Male | 21 | 2023 | 364203 | 0.100 |
Why?
|
| PAX2 Transcription Factor | 1 | 2012 | 86 | 0.100 |
Why?
|
| Coloboma | 1 | 2012 | 60 | 0.090 |
Why?
|
| Peptides | 1 | 2003 | 4348 | 0.090 |
Why?
|
| Endothelium, Vascular | 1 | 2003 | 4424 | 0.090 |
Why?
|
| Amino Acid Metabolism, Inborn Errors | 1 | 2014 | 283 | 0.090 |
Why?
|
| Tacrolimus | 1 | 2014 | 751 | 0.090 |
Why?
|
| Genetic Predisposition to Disease | 5 | 2019 | 18063 | 0.090 |
Why?
|
| Uremia | 1 | 2011 | 202 | 0.090 |
Why?
|
| Polyneuropathies | 1 | 2011 | 139 | 0.090 |
Why?
|
| Mitochondrial Diseases | 1 | 2014 | 344 | 0.090 |
Why?
|
| Risk Factors | 6 | 2024 | 74886 | 0.090 |
Why?
|
| Postoperative Complications | 2 | 2024 | 15824 | 0.080 |
Why?
|
| Overweight | 1 | 2021 | 2448 | 0.080 |
Why?
|
| Repressor Proteins | 1 | 2020 | 2979 | 0.080 |
Why?
|
| Tissue Donors | 1 | 2019 | 2387 | 0.080 |
Why?
|
| Neutropenia | 1 | 2014 | 892 | 0.080 |
Why?
|
| Biopsy | 3 | 2018 | 6777 | 0.080 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 1 | 2011 | 336 | 0.080 |
Why?
|
| Female | 22 | 2023 | 396660 | 0.080 |
Why?
|
| Treatment Outcome | 9 | 2023 | 65295 | 0.070 |
Why?
|
| Disease Progression | 2 | 2022 | 13646 | 0.070 |
Why?
|
| Apoptosis | 1 | 2023 | 9513 | 0.070 |
Why?
|
| Immunologic Factors | 2 | 2014 | 1592 | 0.070 |
Why?
|
| Heredity | 2 | 2017 | 149 | 0.070 |
Why?
|
| Socioeconomic Factors | 1 | 2021 | 7848 | 0.070 |
Why?
|
| Epigenesis, Genetic | 1 | 2020 | 3828 | 0.070 |
Why?
|
| Thrombocytopenia | 1 | 2014 | 1172 | 0.070 |
Why?
|
| Stem Cell Transplantation | 1 | 2015 | 1596 | 0.070 |
Why?
|
| Antiviral Agents | 1 | 2018 | 3070 | 0.060 |
Why?
|
| Liver Transplantation | 1 | 2017 | 2416 | 0.060 |
Why?
|
| Graft Survival | 3 | 2023 | 3896 | 0.060 |
Why?
|
| Aortic Valve Stenosis | 1 | 2018 | 2021 | 0.060 |
Why?
|
| Arsenic Poisoning | 1 | 2005 | 55 | 0.060 |
Why?
|
| Databases, Genetic | 1 | 2012 | 1758 | 0.060 |
Why?
|
| Herbicides | 1 | 2005 | 104 | 0.060 |
Why?
|
| Review Literature as Topic | 1 | 2006 | 297 | 0.060 |
Why?
|
| Genetic Association Studies | 3 | 2018 | 2744 | 0.060 |
Why?
|
| Hepatocyte Nuclear Factor 1-beta | 1 | 2023 | 93 | 0.050 |
Why?
|
| Body Weight | 1 | 2014 | 4627 | 0.050 |
Why?
|
| DNA-Binding Proteins | 1 | 2020 | 9612 | 0.050 |
Why?
|
| Autoimmune Diseases | 1 | 2015 | 2255 | 0.050 |
Why?
|
| Calcium Oxalate | 1 | 2022 | 75 | 0.050 |
Why?
|
| Central Nervous System Diseases | 1 | 2006 | 518 | 0.050 |
Why?
|
| Phenotype | 4 | 2023 | 16718 | 0.050 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2015 | 3114 | 0.050 |
Why?
|
| Skin | 1 | 2015 | 4499 | 0.050 |
Why?
|
| Antigens, CD20 | 1 | 2022 | 199 | 0.050 |
Why?
|
| Donor Selection | 1 | 2023 | 242 | 0.050 |
Why?
|
| Transcription Factors | 1 | 2020 | 12158 | 0.040 |
Why?
|
| Amphibian Proteins | 1 | 2020 | 35 | 0.040 |
Why?
|
| Genetic Counseling | 1 | 2024 | 635 | 0.040 |
Why?
|
| Age of Onset | 2 | 2017 | 3344 | 0.040 |
Why?
|
| Antigen-Presenting Cells | 1 | 2003 | 960 | 0.040 |
Why?
|
| Obesity | 1 | 2022 | 13085 | 0.040 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2024 | 606 | 0.040 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2023 | 372 | 0.040 |
Why?
|
| Steroids | 2 | 2020 | 937 | 0.040 |
Why?
|
| Larva | 1 | 2020 | 512 | 0.040 |
Why?
|
| Chromosome Deletion | 1 | 2023 | 1384 | 0.040 |
Why?
|
| Cohort Studies | 3 | 2019 | 41718 | 0.040 |
Why?
|
| Xenopus | 1 | 2020 | 710 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2023 | 1733 | 0.040 |
Why?
|
| Perioperative Period | 1 | 2019 | 252 | 0.040 |
Why?
|
| Hypertension | 1 | 2018 | 8615 | 0.040 |
Why?
|
| New England | 1 | 2020 | 1058 | 0.040 |
Why?
|
| Prognosis | 4 | 2019 | 29963 | 0.040 |
Why?
|
| Albumins | 1 | 2019 | 577 | 0.030 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2003 | 1655 | 0.030 |
Why?
|
| Interleukin-2 | 1 | 2023 | 1894 | 0.030 |
Why?
|
| Vasoconstrictor Agents | 1 | 2019 | 655 | 0.030 |
Why?
|
| Aorta, Abdominal | 1 | 2018 | 627 | 0.030 |
Why?
|
| Boston | 2 | 2019 | 9360 | 0.030 |
Why?
|
| Methylmalonyl-CoA Mutase | 1 | 2014 | 23 | 0.030 |
Why?
|
| Erythrocyte Transfusion | 1 | 2019 | 575 | 0.030 |
Why?
|
| Organ Size | 1 | 2019 | 2264 | 0.030 |
Why?
|
| Diet, Protein-Restricted | 1 | 2014 | 73 | 0.030 |
Why?
|
| Heterozygote | 1 | 2020 | 2794 | 0.030 |
Why?
|
| Mutation, Missense | 1 | 2022 | 2592 | 0.030 |
Why?
|
| Nephritis | 1 | 2014 | 146 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2018 | 2276 | 0.030 |
Why?
|
| Antigens, CD | 1 | 2003 | 4032 | 0.030 |
Why?
|
| Adult | 3 | 2023 | 223317 | 0.030 |
Why?
|
| Membrane Glycoproteins | 1 | 2003 | 3702 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2018 | 1443 | 0.030 |
Why?
|
| Kidney Tubules, Proximal | 1 | 2014 | 386 | 0.020 |
Why?
|
| Infant Mortality | 1 | 2017 | 752 | 0.020 |
Why?
|
| Sural Nerve | 1 | 2011 | 105 | 0.020 |
Why?
|
| Prospective Studies | 3 | 2022 | 54886 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2018 | 2428 | 0.020 |
Why?
|
| Vitamin B 12 | 1 | 2014 | 529 | 0.020 |
Why?
|
| Predictive Value of Tests | 2 | 2017 | 15424 | 0.020 |
Why?
|
| Alleles | 1 | 2021 | 6893 | 0.020 |
Why?
|
| Health Surveys | 1 | 2020 | 4056 | 0.020 |
Why?
|
| Young Adult | 4 | 2019 | 59980 | 0.020 |
Why?
|
| Neural Conduction | 1 | 2011 | 442 | 0.020 |
Why?
|
| Disease Susceptibility | 1 | 2017 | 1791 | 0.020 |
Why?
|
| Patient Transfer | 1 | 2017 | 788 | 0.020 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2017 | 862 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2020 | 6310 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2003 | 4648 | 0.020 |
Why?
|
| Mice | 3 | 2020 | 81912 | 0.020 |
Why?
|
| Hospitals, Pediatric | 1 | 2019 | 1856 | 0.020 |
Why?
|
| Family | 1 | 2020 | 3210 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2017 | 5022 | 0.020 |
Why?
|
| Atrophy | 1 | 2014 | 1631 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2019 | 6513 | 0.020 |
Why?
|
| Infant, Newborn | 2 | 2020 | 26396 | 0.020 |
Why?
|
| Protein Binding | 1 | 2020 | 9327 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2017 | 4143 | 0.020 |
Why?
|
| Renal Dialysis | 1 | 2017 | 1790 | 0.020 |
Why?
|
| Animals | 4 | 2020 | 168965 | 0.020 |
Why?
|
| Risk Assessment | 2 | 2019 | 24299 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2019 | 10092 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2017 | 3667 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2020 | 8068 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2020 | 14476 | 0.010 |
Why?
|
| Health Personnel | 1 | 2018 | 3387 | 0.010 |
Why?
|
| Recurrence | 1 | 2017 | 8504 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2017 | 6000 | 0.010 |
Why?
|
| Referral and Consultation | 1 | 2017 | 3618 | 0.010 |
Why?
|
| Axons | 1 | 2011 | 1675 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2018 | 14672 | 0.010 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2006 | 696 | 0.010 |
Why?
|
| Hospital Mortality | 1 | 2017 | 5345 | 0.010 |
Why?
|
| Genotype | 1 | 2017 | 13035 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2020 | 22254 | 0.010 |
Why?
|
| Comorbidity | 1 | 2017 | 10582 | 0.010 |
Why?
|
| Pregnancy | 1 | 2023 | 30238 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2018 | 7435 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 15925 | 0.010 |
Why?
|
| Mitochondria | 1 | 2014 | 3678 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2022 | 39317 | 0.010 |
Why?
|
| Family Health | 1 | 2005 | 1254 | 0.010 |
Why?
|
| Lymphoma | 1 | 2006 | 1896 | 0.010 |
Why?
|
| Time Factors | 1 | 2017 | 40154 | 0.010 |
Why?
|
| Radiography | 1 | 2006 | 6975 | 0.010 |
Why?
|
| Acute Disease | 1 | 2005 | 7236 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2017 | 20741 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2006 | 10748 | 0.010 |
Why?
|
| United States | 1 | 2018 | 72971 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2006 | 9245 | 0.010 |
Why?
|